Login / Signup

Multicenter Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease.

Rishika ChughManuel B Braga NetoThomas W FredrickGuilherme P RamosJonathan TerdimanNajwa El-NachefEdward V LoftusUma MahadevanSunanda V Kane
Published in: Journal of Crohn's & colitis (2022)
In this real-world cohort of highly refractory Crohn's disease patients, upadacitinib was effective in inducing remission and had an acceptable safety profile.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • clinical trial
  • disease activity
  • rheumatoid arthritis
  • systemic lupus erythematosus